FEMASYS INC (FEMY) News
Filter FEMY News Items
FEMY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest FEMY News From Around the Web
Below are the latest news stories about FEMASYS INC that investors may wish to consider to help them evaluate FEMY as an investment opportunity.
Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeedHRC Fertility to begin providing FemaSeed infertility treatment to patients at centers across CaliforniaATLANTA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces a partnership with HRC Fertility, one of the largest and most established providers of IVF and fertility services in |
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility TreatmentTrial results demonstrated safety and effectiveness of FemaSeed intratubal insemination with high satisfaction ratings from both practitioners and patientsATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces the peer-reviewed publication of positive data from its pivotal tria |
Femasys Third Quarter 2024 Earnings: Misses ExpectationsFemasys ( NASDAQ:FEMY ) Third Quarter 2024 Results Key Financial Results Revenue: US$554.9k (up 127% from 3Q 2023). Net... |
Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue EstimatesFemasys (FEMY) delivered earnings and revenue surprises of -20% and 38.75%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate UpdateCompany accelerated commercialization with significant new partnerships both in the U.S. and EuropeATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended September 30, 2024 and provides a corporate update. Corporate Highlights from 3Q 2024 |
Femasys to Exhibit at the Annual AAGL 2024 Global ConferencePremier conference focused on gynecological surgeryATLANTA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company will be exhibiting at the American Association of Gynecologic Laparoscopists (AAGL) 2024 Annual Global Conference, being held November 16-19 in New Orlea |
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth ControlFemBloc issued patent provides additional coverage for Femasys’ therapeutic option for women seeking permanent birth controlATLANTA, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the United States Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 12,12796 coveri |
Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeedBoston IVF to begin providing FemaSeed as an infertility treatment option to expand access for patients across nearly 30 centers nationwideATLANTA, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces a partnership with Boston IVF, one of the largest providers of fertility services |
Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education ProgramCompany’s VP of Education and Global Training Named Chairman of ASRM Corporate Member CouncilATLANTA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company will be exhibiting at the American Society of Reproductive Medicine’s (ASRM) 2024 Scientific Congress and Expo, |
Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual SummitATLANTA, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that Kathy Lee-Sepsick, Founder, President, and CEO, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at |